Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELASBRIDGE
2022-500299-71-00Phase 2Authorised
- Sponsor
- CHU de Nantes
- Start
- May 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of belatacept in kidney allograft rejection, sponsored by CHU de Nantes. Primary endpoint: Feasibility of reintroduction of calcineurin inhibitors. Planned start May 2022; status: authorised.
02
Drugs
belatacept
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2022-500299-71-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500299-71-00.